Category Archives for "News"

Seattle, WA - December 26, 2023, — Global E∙dentity™, a Delaware corporation and a prominent innovator in biometric technology, has formally extended a legally binding offer of $5.5 million to the Board of Directors of Amazon (NASDAQ: AMZN). This offer signifies a strong and genuine interest in acquiring Amazon One. The proposal outlines a transformative vision for the future of biometric technology.

Despite previous correspondence, a response from Amazon CEO Mr. Jassy is still pending. In light of this, Global E-dentity has initiated discussions through well-established connections, including Senator Marsha Blackburn, Congressman Mark Green's office, and Mike Ward, the Republican lobbyist retained by the Amazon Board of Directors.

Global E-dentity's offer encompasses the acquisition of Amazon One's software, including associated patents. This proposal excludes the "Amazon One" name and the retention of existing staff while ensuring a seamless transition.

Amazon One, with a current estimated revenue of approximately $102,000.00, employs Palm Print with single vascular biometrics. Global E-dentity aims to replace outdated patented hardware with their US Patent 10,721,228 for Multi-dimensional Vascular/Vein biometrics, a highly secure and faster solution, scalable on a global level and across personal devices. The proposed technology features "dual Liveliness, heartbeat, and Blood flow" scanning capabilities, executing scans in a mere 200 milliseconds by using the advanced cameras in most devices.

The redesigned software will be compatible with various modern external hardware devices, such as mobile devices, laptops, tablets, and watches. This facilitates our global Point of Sale, banking, and identity services, incorporating health detection biometrics. Allowing for the current customers like Panera Bread and Whole Foods to simply build the IP and biometrics algorithms into their customer's application, thus not more specialized Amazon hardware, then we can scale this on a global level much faster using the advanced mobile phones.

Global E-dentity's offer includes an all-cash sum, the proposal aligns with the company's commitment to advancing biometric technology on a global scale, with ongoing projects including a collaboration with the U.S. Government and Singapore Government.

Dr. Adams, stated, "Our offer is straightforward and fair, presenting an opportunity for Amazon to embrace the future of biometrics and fortify its position in the digital realm. We appreciate Amazon's BOD consideration during this pivotal moment, especially given the company's public status and our forthcoming public offering."

About Global e·dentity™

Global e·dentity™ Inc. is a registered corporation in Delaware and is a leading provider of multi-factor biometrics, digital identity solutions, and health biometrics. For more information, please visit www.globaledentity.com. Global e·dentity™ and its product(s) are either registered trademarks or trademarks of Global e·dentity™ Inc. in the United States and/or other countries. 

For further information, contact:

Global E-dentity Corporate Communications
Sophia Miller
Email: [email protected]

Wilmington, DE –March 13, 2023 — Global e-dentity, a leader in innovative health biometrics technology, has announced a groundbreaking advancement in glucose level detection.

The company has leveraged its patented chemosensory technology (US11277405B2) to create a non-invasive method for measuring blood sugar levels, building the sensors into popular smartwatches such as the Apple Watch or Samsung Galaxy Watch. With this new technology, glucose levels can now be monitored through a wearable device like a watch, offering wearers greater independence and lifestyle control, thus eliminating painful and inconvenient daily blood tests. The company has announced that it will now seek FDA emergency approval to bring this technology to market as soon as possible.

Global e-dentity's chemosensory technology uses sensors that detect changes in the levels of volatile organic compounds (VOCs) present and emmitted by the wearer's body. The blood inside the body is also an important source of body odors because some metabolically produced VOCs are secreted into the blood and eventually emitted to the external environment via skin and/or sweat. By analyzing these VOCs with Global e-dentity’s Machine Learning AI, the technology can accurately determine the patient's glucose levels in real-time, without requiring any blood samples.

"We are thrilled to have developed this technology, our team has worked hard on this the last two years to define the healthy baseline, and create the Algorithm that can detect the delta between healthy glucose levels and raised glucose levels, this team is committed to making it available to users as soon as possible," said Dr. Robert Adams, CEO of Global e-dentity. "With FDA emergency approval, we can help people manage their diabetes more effectively, without the need for costly, inconvenient, and expensive tests." With the sensors integrated into popular smartwatches such as the Apple Watch or Samsung Galaxy Watch, users can now monitor their glucose levels discreetly and effortlessly. The smartwatch app can alert users to any changes in their glucose levels, helping them manage their diabetes more effectively.

This breakthrough comes at a time when diabetes is becoming a growing concern worldwide. According to the World Health Organization, approximately 463 million adults were living with diabetes in 2019. With this new technology, users can easily and painlessly monitor their glucose levels using advanced AI technology, leading to better management of their condition.

Global e-dentity's patented chemosensory biometrics technology is set to disrupt the healthcare industry and improve the lives of millions of people worldwide. The company is committed to working closely with regulatory bodies and healthcare providers & manufacture’s to bring this technology to market as quickly and safely as possible. The app will be available for download on the Apple App Store or Google Play Store, pending the FDA emergency approval.

Wilmington, DE –December 12, 2022, the Global e-dentity group underlines its humanitarian commitment to saving lives and helping to stop the spread of Covid in China through its patented biometric technology. As of 08 December 2022, a joint venture between the Global e- dentity group & Covid Biometrics China, (GCBC) will operate until 2038.

“Today marks an important step not just with China but with the world, as countries seek to ensure public health protections while facilitating economic growth in the Covid era. The Chinese government over the last 8 months has worked with our engineering teams to design the hardware that will utilize our intellectual property and will soon start using Covid screening devices. The joint venture lays the foundation for sustainable public health success, while simultaneously facilitating growth and prosperity in China and beyond,” said Dr. Adams, Chairman of the Board of Management and CEO of Global e-dentity.

Global e-dentity, led by senior vice president Dr. Elvis Tan and CEO Dr. Robert Adams, toured key production plants and R&D centers in China and had a series of meetings focused on core technologies and components to fulfill Covid detection requirements over the last 8 months. They also met with a senior team from the Chinese government’s health agency. Global e-dentity’s Singapore subsidiary specializing in AI software for Covid Detection was also involved. The two executives tested the handheld scanning devices developed by several Chinese companies around Global e-identity intellectual property that uses chemosensory technique to smell for the detectable odor a body emits when infected by Covid.

According to Dr Adams, “The process is quite simple and works on two principles, one being Chemosensory and the other utilizing light along with a 3D Ultrasound imaging sensor. This can identify in seconds those who are actively infected with Covid.”

“Chinese scientists have been able to reduce the light transducer, the 3D ultrasound, and organic chemosensory sensors down to a size of about 3mm & 12mm and the scan time has been reduced from 8 seconds to only 3 seconds. With further US and China joint technology efforts, we expect to reduce the chemosensory sensor down to 1mm or less and by 2024 be ready for use in IoT devices, smartwatches, and smart rings. We are confident that technology will soon permitchemosensory (smell) sensors that detect diseases like Covid to be built into an application downloaded to mobile phones. China will now start to deploy scanners as one new element of an effort to manage Covid, enhancing their ability to promote public health and ensure economic growth.”

Dr. Adams, Chairman, and CEO of Global e-dentity further commented, "We are witnessing a remarkable development, moving in less than a year from a prototype to the first fully functional chemosensory scanners. As health and identity biometrics merge, countries around the world have a new way of achieving critical humanitarian goals during times of complex spread of communicable diseases – keeping people safe while allowing necessary work and private activities to continue.”

Wilmington, DE –June 28, 2022 — Biometric identification startup company Global e·dentity™ Inc., has received its seventh U.S. Patent in three years from the US Patent & Trade Office (PTO), patent number US 11,374,929 BIOMETRIC AUTHENTICATIONS FOR AN AUGMENTED REALITY OR A VIRTUAL REALITY DEVICE. Global e·dentity™ Inc.’s technology enables VR/AR companies and developers to add secure biometrics to positively verify individual identity transactions including airline travel, port of entry identification, and banking transactions. Global e·dentity™ Inc.’s patented technology protects individual user privacy, yet ensures a positive identity, regardless of facial features or skin tone. Using biometric authentication enhanced with a multimodal matching unique to a specific living user, the Global e·dentity™ technology involves non-evasive scanning to generate a multi-dimensional image specific to each individual. 

This latest Global e·dentity™ patent further enables organizations or countries using the company’s market-leading biometric identification technology to non-evasively scan for both 100% personal identification and health-related biometric markers, as necessary. 

“This new patent recognizes our rapidly expanding capabilities in the biometric identification field, building upon our technology and previous six patents to accomplish not only personal individual identification but also early identification of health issues,” says Global e·dentity™ Founder Dr. Robert Adams. “Our technology can now be used in VR/AR wearables mobile devices to aid in teaching or for health screening during regular biometric identity checks at home or remote locations. Global e·dentity™ uses various sensors, this is what brands us and makes us different and unique in the biometric identification industry.”

Wilmington, DE –June 21, 2022 — Biometric identification startup company Global e·dentity™ Inc., has received its sixth U.S. Patent in three years from the US Patent & Trade Office (PTO), patent number US 11,368,455. Global e·dentity™ technology enables international transportation and safety agencies like TSA (Transportation Security Administration) to positively verify individual identity without using easily fooled technologies like facial recognition software, fingerprints, or retina scans used by other companies. Global e·dentity™ method protects individual user privacy, yet ensures a positive identity, regardless of facial features or skin tone. Using a multi-dimensional vascular biometric authentication is the most secure method, as it has security built-in with a vascular matching unique to a specific living user to generate a multi-dimensional vascular image matched to the specific individual user. 

This latest Global e·dentity™ patent further enables organizations or countries using the company’s patented market-leading biometric identification technology to non-evasively scan for both 100% personal identification and health-related biometric markers, as necessary.   Global e-dentity’s™ identification with health screening can also be accomplished during the biometric identity checks or can be built into mobile technology to be used at screening locations like border crossings and airports, using either ultrasound, NIR, or near-infrared spectroscopy (NIRS) sensors.

Wilmington, DE –March 15, 2022 — Biometric identification startup company Global e·dentity™ Inc., has received its fifth U.S. Patent and Trade Office (PTO) patent number US 11,277,405 DUAL BIOMETRIC AUTHENTICATION AND BIOMETRIC HEALTH MONITORING USING CHEMOSENSORY AND INTERNAL IMAGING DATA. Last year, the American tech start-up patented the first biotechnology solution enabling users to instantly detect pre-symptomatic or asymptomatic Covid-19 infections through unique odors emitted by the human body, and the new patent expands upon that technology.

Global e·dentity’s™ newest patent is the company’s second continuation U.S. patent to use health biometric chemosensory (smell) scanning to identify individuals’ health profiles during the identity confirmation. This latest Global e·dentity™ patent further enables organizations or countries using the company’s market-leading biometric identification technology to scan for both 100% personal identification and health-related biometric markers. The company’s fifth patent recognizes the Global e·dentity™ team’s groundbreaking development of advanced multimodal biometric identification/health biometrics related technology.

“This new patent recognizes the broadening of our capabilities, powerfully illustrating how Global e·dentity™ Inc. multimodal chemosensory biometrics can be used for personal individual identification and early identification of health issues including COVID-19,” says Global e·dentity™ Founder Dr. Robert Adams. Global e-dentity’s™ identity & health screening can be accomplished during regular biometric identification onboarding and can be built into mobile phones, cars, and/or screening locations like border crossings or airports using ultra-sound sensors, NIR sensors, or chemosensory scanning sensors. The technology uses scanning, linked to multi-modal biometric identification that is absolutely unique to each individual.

Global e•dentity™ Receives First U.S. Patent For COVID-19 Detection

Wilmington, DE –Dec 29, 2020 — Global e·dentity™ Inc, the biometric identification startup, has received its fourth U.S. Patent and Trade Office (PTO) patent number US 10,880,303 REAL-TIME COVID-19 OUTBREAK IDENTIFICATION WITH NON-INVASIVE, INTERNAL IMAGING FOR DUAL BIOMETRIC AUTHENTICATION AND BIOMETRIC HEALTH MONITORING.

Global e·dentity’s™ newest patent is the first U.S. patent (and the first identified technology in the world) to use biometric scanning to identify individuals who are asymptomatic or pre-symptomatic for Covid-19 or SARS. This latest Global e·dentity™ patent enables organizations or countries using the company’s market-leading biometric identification technology to scan for both 100% personal identification and Covid-19 or SARS by Chemosensory.

Global e∙dentity™ Inc. Third Biometrics Technology patent issued by US PTO

Wilmington, DE – Aug 3, 2020 — Global e·dentity™ Inc, the biometric identification startup, received its third U.S. Patent and Trade Office (PTO) patent number US 10,721,228 in less than 180 days. Global e·dentity’s™ newest patent is a continuation of Multimodal Biometric and Digital Identity original patent US 10,135,822 issued in November 2018, and recognizes the Global e·dentity™ team’s groundbreaking work developing an advanced multi-modal biometric identification/health technology.

Global e∙dentity™ Proposes Biometric Technology to Identify Asymptomatic Individuals with suspected Covid-19 infection

Wilmington, DE – July 29, 2020 — Global e∙dentity™ a national security biometric tech startup founded by U.S. Navy veteran Robert Adams, has proposed a simple biometric technology that can also be used to identify individuals infected asymptomatically with the Covid-19 infection.

Wilmington, DE – December 31, 2019 — Global e∙dentity™, the biometric identification startup founded by U.S. Navy veteran Robert Adams, was selected by The Tech Tribune,
a CrunchBase venture that each year selects the top ten company’s in each state. The Tech Tribune recognizes the Global e∙dentity™ http://thetechtribune.com/3-best-tech-startups-in-delaware/ team’s groundbreaking work developing a new biometric identification system and Health biometrics monitoring technology.

“I am humbled by the team’s efforts and surprised with all the other contenders whom I see as bigger than our company,” says Adams. “Our now multi patented technology covers a non-invasive way of validating anyone’s identity, like differentiating biological twins; our technology solves problems that old biometric technology, including the facial and iris scans being used by many of today’s tech giants, have not solved. Issues like misidentification of individuals with darker skin pigmentation or even stolen personal biometric markers won’t fool our tech, as our multimodal match rate is one is 7.53Billion.”

Global e∙dentity™ Second Patent issued in less than one year

Wilmington, DE – November 26, 2019 — Global e∙dentity™, the biometric identification startup founded by U.S. Navy veteran Robert Adams, has received its second US PTO patent No. 10,547,611. Global e∙dentity’s™ patent is a continuation of Multimodal Biometric and Digital Identity original patent US 10,135,822, and recognizes the Global e∙dentity™ team’s groundbreaking work developing a new biometric identification system and technology. 

We were featured in Venture Nashville Connections on our biometrics technology.